Filing Details
- Accession Number:
- 0001140361-10-032746
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2010-08-11 13:00:00
- Reporting Period:
- 2010-08-10
- Filing Date:
- 2010-08-11
- Accepted Time:
- 2010-08-11 14:43:18
- SEC Url:
- Form 4 Filing
Issuer
| Cik | Name | Symbol | Sector (SIC) | IRS No |
|---|---|---|---|---|
| 874716 | Idexx Laboratories Inc | IDXX | In Vitro & In Vivo Diagnostic Substances (2835) | 010393723 |
Insiders
| Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
|---|---|---|---|---|---|---|---|
| 1023869 | Merilee Raines | One Idexx Drive Westbrook ME 04092 | Corporate Vp & Cfo | No | Yes | No | No |
Reported Non-Derivative Transactions
| Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|---|---|---|---|---|---|
| Common Stock | Acquisiton | 2010-08-10 | 10,578 | $11.34 | 156,059 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2010-08-10 | 16,000 | $13.32 | 172,059 | No | 4 | M | Direct | |
| Common Stock | Acquisiton | 2010-08-10 | 29,422 | $11.34 | 201,481 | No | 4 | M | Direct | |
| Common Stock | Disposition | 2010-08-10 | 31,500 | $59.02 | 169,981 | No | 4 | S | Direct |
| Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
|---|---|---|---|---|
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | M | Direct | |
| No | 4 | S | Direct |
Reported Derivative Transactions
| Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
|---|---|---|---|---|---|---|---|
| Common Stock | Incentive Stock Option (right to buy) | Disposition | 2010-08-10 | 10,578 | $0.00 | 10,578 | $11.34 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2010-08-10 | 16,000 | $0.00 | 16,000 | $13.32 |
| Common Stock | Non-Qualified Stock Option (right to buy) | Disposition | 2010-08-10 | 29,422 | $0.00 | 29,422 | $11.34 |
| Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
|---|---|---|---|---|---|---|
| 0 | 2011-02-07 | No | 4 | M | Direct | |
| 15,796 | 2012-02-12 | No | 4 | M | Direct | |
| 0 | 2011-02-07 | No | 4 | M | Direct |
Footnotes
- The sale price reported reflects the weighted average sale price of multiple transactions on the reported date at prices that ranged from $58.82 to $59.39, inclusive. The reporting person hereby undertakes to provide upon request to SEC staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price within the range.
- Grant of options to buy shares of common stock becomes exercisable as to 2,578 shares on 2/7/2005 and 8,000 shares on 2/7/2006.
- Grant of options to buy shares of common stock becomes exercisable as to 8,000 shares on 2/12/2003, 2/12/2004 and 2/12/2005, 7,306 shares on 2/12/2006, and the remaining 490 shares on 2/12/2007.
- Grant of options to buy shares of common stock becomes exercisable as to 8,000 shares on 2/7/2002, 2/7/2003 and 2/7/2004, and the remaining 5,422 shares on 2/7/2005.
Billionaire Hedge Funds
